

A Simple LC-MS/MS Method for Simultaneous Analysis of 35 Anti-psychotics in Human Plasma for Clinical Research

Bilgin Vatansever, Dominic Foley, Gareth Hammond, Lisa J. Calton

Waters Corporation

연구용으로만 사용할 수 있습니다. 진단 절차에는 사용할 수 없습니다.

Abstract

LC-MS/MS is a technique which allows selective and analytically sensitive analysis of large panels in single run sets. In this application note, we describe a simple and robust clinical research method for the simultaneous analysis of 35 antipsychotics in human plasma using an ACQUITY™ UPLC™ I-Class System coupled with a Xevo™ TQ-S micro Mass Spectrometer as a tool in clinical research.

Benefits

- A method for simultaneous quantification of 35 antipsychotics in human plasma within one single LC-MS/MS run
- Simple and cost-effective sample preparation
- Injection to injection time of less than five minutes

Introduction

Antipsychotic drugs are widely used in combination with other drugs leading to potential pharmacokinetic (PK) and pharmacodynamic (PD) drug interactions. Many of these interactions have not been adequately studied for clinical research.¹ Herein, we demonstrate a simple, cost-effective, fast and robust LC-MS method which is based on protein precipitation for simultaneous analysis of 35 antipsychotics drugs in human plasma. The verification of the method was performed including the functional sensitivity, linearity, extraction recovery, matrix effects, interferences, and autosampler stability.

Experimental

The calibration ranges and quality control (QC) sample concentrations for all 35 compounds are shown in Table 1.

Analytes	Calibration range (ng/mL)	QC concentrations (ng/mL)
Benperidol, Flupentixol, Fluphenazine, Haloperidol, Guanfacine, Iloperidone, Loxapine, Perphenazine and Asenapine	0.5–50	2, 10 and 40
Bromperidol, Cariprazine and Zuclopenthixol	1.0–100	4, 20 and 80
Brexpiprazole, Chlorprothixene, Norolanzapine (N-Desmethyloanzapine), Levomepromazine, Melperone, Olanzapine, Perazine, Paliperidone (9-Hydroxyrisperidone), Prothipendyl, Risperidone, Sertindole, Ziprasidone and Zotepine	5.0–500	20, 100 and 400
Amisulpride, Chlorpromazine, Norquetiapine (N-Desalkylquetiapine), Pipamperone and Promethazine	10–1000	40, 200 and 800
Clozapine, Quetiapine, Sulpiride, Sulfuridazine (Thioridazine-2-sulfone) and Thioridazine	20–2000	80, 400 and 1600

Table 1. Calibration and QC concentrations.

The calibration standards consisted were prepared from the working solutions containing the 35 analytes at 5 different concentration levels. (See Table 1) A mixture of stable isotope labeled internal standards (SIL-IS) at different concentrations corresponding to the appropriate calibration ranges of the antipsychotic compounds were prepared directly in protein precipitation solvent (PPS). The PPS was a mixture of 70:30 (v:v) MeOH:0.1M ZnSO_{4(aq)}.

To 50 µL of plasma, 100 µL of PPS was added and all samples were vortex mixed briefly before centrifugation at 18,000 g for five minutes at room temperature. 100 µL of the supernatant was transferred into a 96-well plate (Waters™ 1ml Round Collection Plate, p/n: 186002481 <<https://www.waters.com/nextgen/global/shop/vials-containers--collection-plates/186002481-96-well-sample-collection-plate-800--l-round-well-50-pk.html>>) and then diluted with 100 µL distilled pure water. The samples in the plate were mixed on a shaker for three minutes at 850 rpm and room temperature prior to analysis by LC-MS/MS using multiple reaction monitoring (MRM).

A Waters Xevo TQ-S micro Triple Quadrupole Mass Spectrometer coupled to an ACQUITY UPLC I-Class System with FL Sample Manager was used for all analyses. Ionization was achieved using electrospray in the positive ionization mode (ES+). Details of the MRM conditions are given in Table 2.

LC Conditions

LC system:	ACQUITY UPLC I-Class System with FL Sample Manager
Column:	XSelect™ HSS C18 SB XP Column, 100 Å, 2.5 µm, 2.1 mm x 30 mm, (p/n: 186006160)
Column temperature:	45 °C (pre-column heater active)
Sample temperature:	5 °C ± 2° C
Loop volume:	50 µL
Injection volume:	15 µL
Flow rate:	0.600 mL/min
Mobile phase A:	2 mM ammonium acetate in Water + 0.1% formic acid

Mobile phase B: 2 mM ammonium acetate in Methanol + 0.1% formic acid

Seal wash: 20% aqueous methanol

Weak wash: 5:95 (v:v) methanol:water

Weak wash volume: 2 mL

Strong wash: 25:25:25:25 (v:v:v:v)
water:methanol:acetonitrile:2-propanol

Strong wash volume: 2 mL

Gradient Table

Time (min)	Flow rate (mL/min)	%A	%B	Curve
initial	0.6	90	10	initial
0.5	0.6	90	10	6
3.0	0.6	25	75	6
3.1	0.6	0	100	11
3.8	0.6	90	10	11
Run time:	4.3 minutes (4.9 minutes injection to injection)			

Function: (acquisition) time	Analytes	RT	Parent ion (m/z)	Daughter ion (m/z)	Dwell time (s)	Cone voltage (V)	Collision energy (V)
Function: 1 (0.10–1.85)	Guanfacine	1.50	246.0	60.0 (158.9)	0.009	30	16 (24)
	Guanfacine- ¹⁵ C, ¹⁵ N ₃ (IS)	1.50	250.0	64.1	0.009	30	16
	Norolanzapine	1.06	299.1	256.1 (70.0)	0.009	20	24 (24)
	d8-Norolanzapine (IS)	1.06	307.2	198.0	0.009	20	24
	Olanzapine	1.24	313.2	256.1 (84.1)	0.009	25	18 (18)
	d3-Olanzapine (IS)	1.23	316.2	256.1	0.009	25	18
	Amisulpride	1.66	370.1	242.0 (196.0)	0.009	16	22 (40)
	d5-Amisulpride (IS)	1.66	375.2	242.0	0.009	16	22
	Pipamperone	1.42	376.2	165.0 (123.0)	0.009	24	26 (40)
	d10-Pipamperone (IS)	1.35	386.3	165.0	0.009	24	26
	Sulpiride	0.99	342.1	112.1 (214.0)	0.009	20	30 (23)
	d3-Sulpiride (IS)	0.98	345.2	112.1	0.009	20	30
Function: 2 (1.80–2.20)	(*) Benperidol	1.99	382.2	123.0 (165.1)	0.008	20	38 (22)
	Melperone	1.90	264.2	123.0 (95.0)	0.008	20	26 (46)
	d4-Melperone (IS)	1.90	268.2	127.0	0.008	20	26
	Paliperidone	1.95	427.2	207.1 (110.0)	0.008	30	24 (38)
	d4-Paliperidone (IS)	1.95	431.2	211.1	0.008	30	24
	Norquetiapine	2.07	296.1	210.1 (221.1)	0.008	20	22 (22)
	d8-Norquetiapine (IS)	2.04	304.2	210.0	0.008	20	22
Function: 3 (2.25–2.55)	Iloperidone	2.37	427.4	261.1 (233.1)	0.003	50	26 (26)
	d3-Iloperidone (IS)	2.36	430.4	261.1	0.003	50	26
	Loxapine	2.37	328.1	271.0 (84.1)	0.003	30	20 (16)
	d8-Loxapine (IS)	2.37	336.2	276.2	0.003	30	20
	Cariprazine	2.42	427.2	46.0 (188.0)	0.003	20 (20)	36 (36)
	d8-Cariprazine (IS)	2.42	435.3	188.0	0.003	20	36
	Brexiprazole	2.39	434.2	273.1 (98.0)	0.003	20	20 (36)
	d8-Brexiprazole (IS)	2.38	442.2	281.2	0.003	20	20
	Prothipendyl	2.38	286.1	241.1 (213.0)	0.003	20	13 (26)
	d6-Prothipendyl (IS)	2.38	292.2	241.1	0.003	20	13
	Promethazine	2.41	285.1	86.1 (198.0)	0.003	16	10 (20)
	d6-Promethazine (IS)	2.41	291.2	92.2	0.003	16	10
	Sulfuridazine	2.34	403.1	98.0 (126.1)	0.003	20	38 (22)
	d3-Sulfuridazine (IS)	2.34	406.6	101.1	0.003	20	38

Function: (acquisition time)	Analytes	RT	Parent ion (m/z)	Daughter ion (m/z)	Dwell time (s)	Cone voltage (V)	Collision energy (V)
Function: 4 (2.12–2.45)	Haloperidol	2.17	376.2	165.1 (123.0)	0.006	26	18 (36)
	d4-Haloperidol (IS)	2.17	380.1	165.1	0.006	26	18
	Asenapine	2.29	286.1	44.0 (229.0)	0.006	40	24 (16)
	d3-Asenapine- ¹³ C (IS)	2.29	290.2	48.1	0.006	40	24
	(*)Bromperidol	2.22	420.0	165.1 (123.0)	0.006	20	22 (38)
	Risperidone	2.23	411.2	191.1 (82.1)	0.006	24	22 (60)
	d4-Risperidone (IS)	2.22	415.2	195.2	0.006	24	22
	Ziprasidone	2.16	413.1	194.0 (166.1)	0.006	24	22 (46)
	d8-Ziprasidone (IS)	2.15	421.1	194.1	0.006	34	22
	Clozapine	2.20	327.1	192.0 (270.1)	0.006	30	36 (18)
	d4-Clozapine (IS)	2.18	331.2	192.0	0.006	30	36
	Quetiapine	2.25	384.2	253.1 (221.1)	0.006	20	34 (20)
	d8-Quetiapine (IS)	2.23	392.2	225.9	0.006	20	34
Function: 5 (2.50–3.50)	Flupentixol	2.93	435.2	100.0 (305.1)	0.003	10	26 (26)
	d4-Flupentixol (IS)	2.93	439.2	305.1	0.003	10	26
	Fluphenazine	2.85	438.2	171.2 (143.1)	0.003	30	20 (26)
	d8-Fluphenazine (IS)	2.85	446.1	179.2	0.003	30	20
	Perphenazine	2.77	404.1	171.1 (70.1)	0.003	38	16 (46)
	d4-Perphenazine (IS)	2.77	408.2	171.1	0.003	38	16
	Zuclopenthixol	2.85	401.1	100.0 (231.0)	0.003	25	24 (28)
	d4-Zuclopenthixol (IS)	2.85	405.2	104.0	0.003	25	24
	Chlorprothixene	2.72	316.1	271.1 (231.0)	0.003	25	15 (25)
	d6-Chlorprothixene (IS)	2.72	322.1	271.1	0.003	25	15
	Perazine	2.68	340.2	141.2 (70.1)	0.003	30	14 (38)
	d8-Perazine (IS)	2.66	348.2	149.2	0.003	30	14
	Sertindole	2.90	441.2	113.0 (70.3)	0.003	24	28 (58)
	d4-Sertindole (IS)	2.90	445.2	117.1	0.003	24	28
	Zotepine	2.74	332.1	72.1 (44.1)	0.003	10	14 (55)
	d6-Zotepine (IS)	2.74	338.1	78.1	0.003	10	14
	Chlorpromazine	2.68	319.1	86.1 (58.1)	0.003	20	15 (34)
	d6-Chlorpromazine (IS)	2.68	325.2	92.1	0.003	20	15
	Thioridazine	2.88	371.2	126.2 (98.0)	0.003	35	18 (32)
	d3-Thioridazine (IS)	2.88	374.2	129.4	0.003	35	18
Function: 6 (2.45–2.75)	Levomepromazine	2.58	329.2	58.1 (100.0)	0.003	26	28 (14)
	d6-Levomepromazine (IS)	2.58	335.2	64.1	0.003	26	28

Table 2. MRM transitions and parameters of all individual quantifier compounds and their corresponding internal standards (SIL-IS). Qualifier ion parameters are shown in parentheses. () Analogue internal standards d8-Quetiapine and d8-Brexipiprazole are used for quantification of Benperidol and Bromperidol, respectively.*

MS Conditions

MS system:	Xevo TQ-S micro Tandem Quadrupole Mass Spectrometer
Resolution:	MS1 (0.75 FWHM) MS2 (0.75 FWHM)
Polarity:	ESI+ ionization
Acquisition mode:	MRM (see Table 2 for details)
Capillary voltage:	0.5 V
Desolvation temperature:	650 °C
Desolvation (L/Hr):	1000
Cone (L/hr):	0
MS Inter-scan:	0.003 seconds
Polarity/Mode switch inter-scan:	0.015 seconds
Inter-channel delay:	0.002 seconds

Data Management

Chromatography software:	MassLynx Mass Spectrometry Software™ V4.2 (SCN1045)
MS software:	MassLynx Mass Spectrometry Software V4.2 (SCN1045)

Results and Discussion

Method verification was performed through assessment of system carryover, functional sensitivity, linearity, extraction recovery, matrix effects, trueness, repeatability, intermediate precision, accuracy profiles, and autosampler stability. Figure 1 shows the chromatography of all 35 compounds included in the panel on the XSelect HSS C₁₈ SB XP, 100 Å, 2.5 µm, 2.1 mm X 30 mm Column.




Figure 1. Chromatography of all compounds on the ACQUITY UPLC I-Class System XSelect HSS C₁₈ SB XP Column. The earliest eluting compound is sulpiride at 0.97 minutes and the latest eluting compound is flupentixol at 2.93 minutes.

No significant system carryover (<25% Calibrator 1 mean peak area) was observed across all analytes following analysis of a plasma sample at twice the concentration of the high QC.

Functional sensitivity was assessed by extracting and quantifying 10 replicates of low concentration samples prepared in plasma over three days (n=30). Investigations indicated the method would allow for precise quantification ($\leq 20\%$ CV, $\leq 15\%$ bias) at the defined LLMI (Lower Limit of the Measuring Interval) concentrations for each of the analytes.

Linear regression (1/x weighing) provided the best fit, with correlation coefficient (r^2) higher than 0.99 for all analytes. Linearity of the method was also assessed by combining a high concentration pool, above the highest calibrator, with a blank plasma pool. The method was shown to be linear across nine concentration levels ($n=4$) when low and high pools were mixed in known ratios over the ranges of 1.44–240 ng/mL for Benperidol, Flupentixol, Fluphenazine, Haloperidol, Guanfacine, Iloperidone, Loxapine, Perphenazine, and Asenapin; over the ranges of 2.88–480 ng/mL for Bromperidol, Cariprazine and Zuclopenthixol; over the ranges of 14.4–2400 ng/mL for Brexpiprazole, Chlorprothixene, Norolanzapine, Levomepromazine, Melperone, Olanzapine, Perazine, Paliperidone (9-Hydroxyrisperidone), Prothipendyl, Risperidone, Sertindole, Ziprasidone, and Zotepine; over the ranges of 28.8–4800 ng/mL for Amisulpride, Chlorpromazine, Norquetiapine, Pipamperone, and Promethazine; over the ranges of 58.6–9600 ng/mL for Clozapine, Quetiapine, Sulpiride, Sulforidazine and Thioridazine. The allowable non-linearity at all levels for all compounds was less than 10% across the targeted linearity interval. All calculations for linearity assessment were performed using Analyse-it® Software.

Total precision was determined by extracting and quantifying five replicates of three concentrations of plasma pools over five separate days ($n=25$). Repeatability was assessed by analyzing five replicates at each QC level. Total precision and repeatability at the three concentrations for all compounds were shown to be $\leq 8.7\%$ CV and $\leq 7.4\%$, respectively. (see Figure 2 and Figure 3).




Figure 2. Total precision performance.




Figure 3. Repeatability performance.

Normalized matrix effects were evaluated by spiking low and high QC concentrations in plasma of six individuals (n=6) post-extraction and comparing to solvent samples. Calculation using analyte:internal standard response ratio indicated compensation for signal enhancement or suppression by the internal standard. All ratios for normalized matrix effects ranged from 0.88 and 1.14.

Potential interference from endogenous compounds (albumin, bilirubin, cholesterol, creatinine, triglycerides, uric acid) spiked at high concentrations was assessed by determining the recovery (n=3) of the analytes from low and high QC plasma samples. Recoveries for the low QC ranged from 91.5–108.7% and high QC from 85.7–112.7% across all analytes.

Recoveries were evaluated at low and high QC concentrations in plasma of six individuals (n=6) taken as a percentage of extracted plasma samples. The overall mean recovery for each concentration all compounds were in the range of 85%–115%. The mean extraction efficiencies across the 35 analytes ranged from 52.2%–96.9%.

The 72 hours ($5\text{ }^{\circ}\text{C} \pm 2\text{ }^{\circ}\text{C}$) onboard autosampler stability was demonstrated by batch re-analysis of samples (Calibrators, QCs, and Blanks). The determined concentrations of all QC samples were within $\pm 15\%$ deviation of the original determination. Stabilities for QC-low ranged from 93.5–110.5% and QC-high from 97.1–106.6%, respectively.

Conclusion

A method for the LC-MS/MS analysis of 35 anti-psychotics drugs was developed for clinical research. A number of advantages are highlighted:

- The sample preparation and analysis were fast, simple, and inexpensive, requiring only 50 µL of plasma and taking less than five minutes per injection
- Total precision and repeatability were $\leq 8.7\%$ CV and $\leq 7.4\%$, respectively
- The method demonstrated good recovery and extraction efficiency for each analyte with minimal matrix effects

References

1. Wijesinghe R: A review of pharmacokinetic and pharmacodynamic interactions with antipsychotics. *Ment Health Clin* 2016, 6(1):21–27.

Featured Products

[ACQUITY UPLC I-Class PLUS System <](#)

<https://www.waters.com/nextgen/global/products/chromatography/chromatography-systems/acquity-uplc-i-class-plus-system.html>>

[Xevo TQ-S micro Triple Quadrupole Mass Spectrometer <](#)

<https://www.waters.com/nextgen/global/products/mass-spectrometry/mass-spectrometry-systems/xevo-tq-s-micro.html>>

[MassLynx Mass Spectrometry Software <https://www.waters.com/nextgen/global/products/informatics-and-software/mass-spectrometry-software/masslynx-mass-spectrometry-software.html](#)>

[MassLynx Quantitation Applications <https://www.waters.com/nextgen/global/products/informatics-and-software/mass-spectrometry-software/masslynx-mass-spectrometry-software/masslynx-quantitation-applications.html](#)>

720008636, December 2024



© 2025 Waters Corporation. All Rights Reserved.

[이용 약관](#) [개인정보 보호정책](#) [상표](#) [채용정보](#) [법적 고지](#) 및 [개인정보 보호 고지](#) [쿠키](#) [쿠키 기본설정](#)